Reported Earnings • Apr 28
Full year 2025 earnings: EPS misses analyst expectations Full year 2025 results: EPS: CN¥0.19 (up from CN¥0.042 in FY 2024). Revenue: CN¥542.8m (up 20% from FY 2024). Net income: CN¥63.1m (up 450% from FY 2024). Profit margin: 12% (up from 2.5% in FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 24%. Revenue is forecast to grow 21% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has fallen by 62% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings. Announcement • Apr 28
Shanghai Sanyou Medical Co., Ltd, Annual General Meeting, May 21, 2026 Shanghai Sanyou Medical Co., Ltd, Annual General Meeting, May 21, 2026, at 14:00 China Standard Time. Location: The Company's Meeting Room, Shanghai China Announcement • Mar 30
Shanghai Sanyou Medical Co., Ltd to Report Q1, 2026 Results on Apr 28, 2026 Shanghai Sanyou Medical Co., Ltd announced that they will report Q1, 2026 results on Apr 28, 2026 Reported Earnings • Mar 02
Full year 2025 earnings: EPS misses analyst expectations Full year 2025 results: EPS: CN¥0.19 (up from CN¥0.042 in FY 2024). Revenue: CN¥542.8m (up 20% from FY 2024). Net income: CN¥63.3m (up 452% from FY 2024). Profit margin: 12% (up from 2.5% in FY 2024). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 24%. Revenue is forecast to grow 21% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has fallen by 62% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings. New Risk • Feb 20
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Announcement • Dec 26
Shanghai Sanyou Medical Co., Ltd to Report Fiscal Year 2025 Results on Apr 28, 2026 Shanghai Sanyou Medical Co., Ltd announced that they will report fiscal year 2025 results on Apr 28, 2026 Reported Earnings • Oct 28
Third quarter 2025 earnings released: EPS: CN¥0.081 (vs CN¥0.011 in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.081 (up from CN¥0.011 in 3Q 2024). Revenue: CN¥141.7m (up 17% from 3Q 2024). Net income: CN¥25.4m (up 268% from 3Q 2024). Profit margin: 18% (up from 5.7% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 60 percentage points per year, which is a significant difference in performance. Announcement • Sep 30
Shanghai Sanyou Medical Co., Ltd to Report Q3, 2025 Results on Oct 28, 2025 Shanghai Sanyou Medical Co., Ltd announced that they will report Q3, 2025 results on Oct 28, 2025 New Risk • Sep 09
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 39% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Large one-off items impacting financial results. New Risk • Sep 04
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Profit margins are more than 30% lower than last year (5.5% net profit margin). Announcement • Jun 30
Shanghai Sanyou Medical Co., Ltd to Report First Half, 2025 Results on Aug 26, 2025 Shanghai Sanyou Medical Co., Ltd announced that they will report first half, 2025 results on Aug 26, 2025 Announcement • Apr 29
Shanghai Sanyou Medical Co., Ltd, Annual General Meeting, May 23, 2025 Shanghai Sanyou Medical Co., Ltd, Annual General Meeting, May 23, 2025, at 14:30 China Standard Time. Location: The Company's Meeting Room, Shanghai China Announcement • Mar 28
Shanghai Sanyou Medical Co., Ltd to Report Q1, 2025 Results on Apr 29, 2025 Shanghai Sanyou Medical Co., Ltd announced that they will report Q1, 2025 results on Apr 29, 2025 Reported Earnings • Mar 02
Full year 2024 earnings: EPS and revenues miss analyst expectations Full year 2024 results: EPS: CN¥0.05 (down from CN¥0.38 in FY 2023). Revenue: CN¥452.6m (down 1.7% from FY 2023). Net income: CN¥11.3m (down 88% from FY 2023). Profit margin: 2.5% (down from 21% in FY 2023). The decrease in margin was primarily driven by higher expenses. Revenue missed analyst estimates by 6.2%. Earnings per share (EPS) also missed analyst estimates by 74%. Revenue is forecast to grow 28% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings. Announcement • Dec 27
Shanghai Sanyou Medical Co., Ltd to Report Fiscal Year 2024 Results on Apr 29, 2025 Shanghai Sanyou Medical Co., Ltd announced that they will report fiscal year 2024 results on Apr 29, 2025 Reported Earnings • Oct 30
Third quarter 2024 earnings released: EPS: CN¥0.013 (vs CN¥0.014 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.013. Revenue: CN¥120.7m (up 57% from 3Q 2023). Net income: CN¥6.89m (up 105% from 3Q 2023). Profit margin: 5.7% (up from 4.4% in 3Q 2023). Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Medical Equipment industry in China. New Risk • Sep 30
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.2% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (8.8% net profit margin). Announcement • Sep 30
Shanghai Sanyou Medical Co., Ltd to Report Q3, 2024 Results on Oct 29, 2024 Shanghai Sanyou Medical Co., Ltd announced that they will report Q3, 2024 results on Oct 29, 2024 Announcement • Jun 28
Shanghai Sanyou Medical Co., Ltd to Report First Half, 2024 Results on Aug 28, 2024 Shanghai Sanyou Medical Co., Ltd announced that they will report first half, 2024 results on Aug 28, 2024 Buy Or Sell Opportunity • May 30
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 9.4% to CN¥17.98. The fair value is estimated to be CN¥14.85, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 12%. Revenue is forecast to grow by 137% in 2 years. Earnings are forecast to grow by 291% in the next 2 years. New Risk • Apr 28
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 15% Last year net profit margin: 28% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (15% net profit margin). Announcement • Apr 27
Shanghai Sanyou Medical Co., Ltd, Annual General Meeting, May 24, 2024 Shanghai Sanyou Medical Co., Ltd, Annual General Meeting, May 24, 2024, at 14:00 China Standard Time. Location: The Company's Meeting Room, Shanghai China Reported Earnings • Apr 26
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: EPS: CN¥0.38 (down from CN¥0.76 in FY 2022). Revenue: CN¥460.4m (down 29% from FY 2022). Net income: CN¥95.6m (down 50% from FY 2022). Profit margin: 21% (down from 29% in FY 2022). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 17%. Earnings per share (EPS) also missed analyst estimates by 22%. Revenue is forecast to grow 30% p.a. on average during the next 2 years, compared to a 19% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. Announcement • Mar 30
Shanghai Sanyou Medical Co., Ltd to Report Q1, 2024 Results on Apr 26, 2024 Shanghai Sanyou Medical Co., Ltd announced that they will report Q1, 2024 results on Apr 26, 2024 Reported Earnings • Feb 24
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: EPS: CN¥0.37 (down from CN¥0.76 in FY 2022). Revenue: CN¥460.7m (down 29% from FY 2022). Net income: CN¥91.2m (down 52% from FY 2022). Profit margin: 20% (down from 29% in FY 2022). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 17%. Earnings per share (EPS) also missed analyst estimates by 24%. Revenue is forecast to grow 30% p.a. on average during the next 2 years, compared to a 20% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Feb 05
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥13.02, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 17x in the Medical Equipment industry in China. Total loss to shareholders of 54% over the past three years. Announcement • Dec 29
Shanghai Sanyou Medical Co., Ltd to Report Fiscal Year 2023 Results on Apr 26, 2024 Shanghai Sanyou Medical Co., Ltd announced that they will report fiscal year 2023 results on Apr 26, 2024 Buying Opportunity • Nov 30
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 1.0%. The fair value is estimated to be CN¥27.06, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 9.2%. Revenue is forecast to grow by 56% in 2 years. Earnings is forecast to grow by 53% in the next 2 years. Buying Opportunity • Nov 13
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 2.2%. The fair value is estimated to be CN¥27.25, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 9.2%. Revenue is forecast to grow by 69% in 2 years. Earnings is forecast to grow by 86% in the next 2 years. New Risk • Aug 30
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 36% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results. Reported Earnings • Aug 26
Second quarter 2023 earnings released: EPS: CN¥0.11 (vs CN¥0.17 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.11 (down from CN¥0.17 in 2Q 2022). Revenue: CN¥121.4m (down 27% from 2Q 2022). Net income: CN¥28.3m (down 35% from 2Q 2022). Profit margin: 23% (down from 26% in 2Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • May 02
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥32.03, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 26x in the Medical Equipment industry in China. Total loss to shareholders of 26% over the past three years. Reported Earnings • Apr 25
Full year 2022 earnings: EPS and revenues miss analyst expectations Full year 2022 results: EPS: CN¥0.84 (up from CN¥0.83 in FY 2021). Revenue: CN¥649.2m (up 9.4% from FY 2021). Net income: CN¥190.8m (up 2.4% from FY 2021). Profit margin: 29% (down from 31% in FY 2021). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 17%. Earnings per share (EPS) also missed analyst estimates by 9.7%. Revenue is forecast to grow 32% p.a. on average during the next 2 years, compared to a 19% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Feb 22
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥33.41, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 27x in the Medical Equipment industry in China. Total returns to shareholders of 20% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥19.29 per share. Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. 2 independent directors (4 non-independent directors). Independent Director Lijun Xia was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Oct 27
Third quarter 2022 earnings released: EPS: CN¥0.22 (vs CN¥0.19 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.22 (up from CN¥0.19 in 3Q 2021). Revenue: CN¥184.9m (up 17% from 3Q 2021). Net income: CN¥48.0m (up 12% from 3Q 2021). Profit margin: 26% (down from 27% in 3Q 2021). Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Medical Equipment industry in China. Valuation Update With 7 Day Price Move • Oct 17
Investor sentiment improved over the past week After last week's 25% share price gain to CN¥36.24, the stock trades at a forward P/E ratio of 34x. Average forward P/E is 26x in the Medical Equipment industry in China. Total returns to shareholders of 46% over the past year. Valuation Update With 7 Day Price Move • Oct 03
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥29.91, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 23x in the Medical Equipment industry in China. Total returns to shareholders of 20% over the past year. Reported Earnings • Aug 26
Second quarter 2022 earnings released: EPS: CN¥0.18 (vs CN¥0.17 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.18 (up from CN¥0.17 in 2Q 2021). Revenue: CN¥167.1m (up 17% from 2Q 2021). Net income: CN¥43.5m (up 7.3% from 2Q 2021). Profit margin: 26% (down from 28% in 2Q 2021). Over the next year, revenue is forecast to grow 37%, compared to a 26% growth forecast for the Medical Equipment industry in China. Upcoming Dividend • May 31
Upcoming dividend of CN¥0.18 per share Eligible shareholders must have bought the stock before 07 June 2022. Payment date: 07 June 2022. Payout ratio is a comfortable 20% and this is well supported by cash flows. Trailing yield: 0.9%. Lower than top quartile of Chinese dividend payers (2.1%). Lower than average of industry peers (1.4%). Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Reported Earnings • Feb 22
Full year 2021 earnings: EPS and revenues exceed analyst expectations Full year 2021 results: EPS: CN¥0.91 (up from CN¥0.63 in FY 2020). Revenue: CN¥593.4m (up 52% from FY 2020). Net income: CN¥186.4m (up 57% from FY 2020). Profit margin: 31% (up from 30% in FY 2020). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 2.6%. Earnings per share (EPS) also surpassed analyst estimates by 10%. Over the next year, revenue is forecast to grow 32%, compared to a 24% growth forecast for the industry in China. Reported Earnings • Oct 25
Third quarter 2021 earnings released: EPS CN¥0.21 (vs CN¥0.20 in 3Q 2020) The company reported a solid third quarter result with improved earnings and revenues, although profit margins were weaker. Third quarter 2021 results: Revenue: CN¥157.8m (up 33% from 3Q 2020). Net income: CN¥43.0m (up 2.9% from 3Q 2020). Profit margin: 27% (down from 35% in 3Q 2020). The decrease in margin was driven by higher expenses. Valuation Update With 7 Day Price Move • Jul 27
Investor sentiment deteriorated over the past week After last week's 18% share price decline to CN¥34.33, the stock trades at a forward P/E ratio of 41x. Average forward P/E is 36x in the Medical Equipment industry in China. Total loss to shareholders of 51% over the past year. Valuation Update With 7 Day Price Move • Jun 23
Investor sentiment improved over the past week After last week's 29% share price gain to CN¥44.86, the stock trades at a forward P/E ratio of 55x. Average forward P/E is 39x in the Medical Equipment industry in China. Total loss to shareholders of 41% over the past year. Announcement • Jun 04
Shanghai Sanyou Medical Co., Ltd. (SHSE:688085) signed an agreement acquire 49.8% stake in Beijing Shuimu Canopy Medical Technology Co., Ltd. from Suzhou Qiming Fusion Venture Capital Partnership (Limited Partnership), Xinjiang Hongshan Optimal Venture Investment Fund Enterprise (Limited Partnership), Yingtan Haiding Investment Limited Partnership, Xiamen C&D Emerging Industries Equity Investment No. 7 Partnership (Limited Partnership) and Ding Wenjun for approximately CNY 340 million. Shanghai Sanyou Medical Co., Ltd. (SHSE:688085) signed an agreement acquire 49.8% stake in Beijing Shuimu Canopy Medical Technology Co., Ltd. from Suzhou Qiming Fusion Venture Capital Partnership (Limited Partnership), Xinjiang Hongshan Optimal Venture Investment Fund Enterprise (Limited Partnership), Yingtan Haiding Investment Limited Partnership, Xiamen C&D Emerging Industries Equity Investment No. 7 Partnership (Limited Partnership) and Ding Wenjun for approximately CNY 340 million on June 3, 2021.
As per terms of transaction, Shanghai Sanyou Medical Co., Ltd. will use its own funds for the acquisition. Shanghai Sanyou Medical Co., Ltd. will acquire 17.4% stake from Suzhou Qiming Fusion Venture Capital Partnership (Limited Partnership) for CNY 119.8 million, will acquire 3.8% stake from Xinjiang Hongshan Optimal Venture Investment Fund Enterprise (Limited Partnership) for CNY 26.4 million, will acquire 1.9% stake from Yingtan Haiding Investment Limited Partnership for CNY 13.2 million, will acquire 1.9% stake from Xiamen C&D Emerging Industries Equity Investment No. 7 Partnership (Limited Partnership) for CNY 13.2 million and 24.7% stake from Ding Wenjun for CNY 169.9 million.
In a related transaction, Xu Nong will acquire 7.0001% stake in Beijing Shuimu Canopy Medical Technology Co., Ltd. from Cao Qun for CNY 48.1 million on June 3, 2021. Post completion, Shanghai Sanyou Medical Co., Ltd. will hold 51.8154% stake in Beijing Shuimu Canopy Medical Technology Co., Ltd. Beijing Shuimu Canopy Medical Technology Co., Ltd. will become holding subsidiary of Shanghai Sanyou Medical Co., Ltd. As on April 30, 2021, Beijing Shuimu Canopy Medical Technology Co., Ltd. reported total assets of CNY 957.1 million, net assets of CNY 1.2 billion, operating income of CNY 145.7 million and net profit of CNY 4.7 million. Transaction is approved by the board of Shanghai Sanyou Medical Co., Ltd. Announcement • Jun 03
Shanghai Sanyou Medical Plans to Buy Stake in Medical Technology Unit for 342.7 Mln Yuan Shanghai Sanyou Medical Co., Ltd. (SHSE:688085) said it plans to buy 49.9% stake in medical technology unit for CNY 342.7 million. The Company said it will own 51.8% stake in the medical technology firm after transaction. Valuation Update With 7 Day Price Move • May 14
Investor sentiment improved over the past week After last week's 22% share price gain to CN¥38.15, the stock trades at a forward P/E ratio of 47x. Average forward P/E is 38x in the Medical Equipment industry in China. Total loss to shareholders of 42% over the past year. Reported Earnings • Apr 25
First quarter 2021 earnings released: EPS CN¥0.15 (vs CN¥0.08 in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥118.2m (up 138% from 1Q 2020). Net income: CN¥29.9m (up 151% from 1Q 2020). Profit margin: 25% (up from 24% in 1Q 2020). The increase in margin was driven by higher revenue. Valuation Update With 7 Day Price Move • Mar 10
Investor sentiment deteriorated over the past week After last week's 20% share price decline to CN¥29.22, the stock is trading at a trailing P/E ratio of 46.4x, down from the previous P/E ratio of 57.9x. This compares to an average P/E of 41x in the Medical Equipment industry in China. Is New 90 Day High Low • Mar 08
New 90-day low: CN¥34.43 The company is down 16% from its price of CN¥40.80 on 08 December 2020. The Chinese market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥6.04 per share. Reported Earnings • Feb 03
Full year 2020 earnings released: EPS CN¥0.63 (vs CN¥0.64 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥390.4m (up 10% from FY 2019). Net income: CN¥118.8m (up 21% from FY 2019). Profit margin: 30% (up from 28% in FY 2019). The increase in margin was driven by higher revenue. Analyst Estimate Surprise Post Earnings • Feb 03
Earnings beat expectations, revenue disappoints Revenue missed analyst estimates by 2.6%. Earnings per share (EPS) exceeded analyst estimates by 11%. Over the next year, revenue is forecast to grow 50%, compared to a 27% growth forecast for the Medical Equipment industry in China. Is New 90 Day High Low • Jan 11
New 90-day low: CN¥35.52 The company is down 39% from its price of CN¥58.34 on 13 October 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥6.00 per share. Is New 90 Day High Low • Dec 24
New 90-day low: CN¥39.06 The company is down 26% from its price of CN¥53.04 on 24 September 2020. The Chinese market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥5.04 per share. Is New 90 Day High Low • Dec 08
New 90-day low: CN¥40.80 The company is down 33% from its price of CN¥61.10 on 09 September 2020. The Chinese market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥4.35 per share. Is New 90 Day High Low • Nov 17
New 90-day low: CN¥49.34 The company is down 18% from its price of CN¥60.36 on 19 August 2020. The Chinese market is down 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥4.21 per share. Reported Earnings • Oct 26
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥104.5m, up 18% from the prior year. Total revenue was CN¥367.7m over the last 12 months, up 14% from the prior year. Announcement • Oct 19
Shanghai Sanyou Medical Co., Ltd. to Report Q3, 2020 Results on Oct 22, 2020 Shanghai Sanyou Medical Co., Ltd. announced that they will report Q3, 2020 results on Oct 22, 2020 Is New 90 Day High Low • Oct 01
New 90-day low: CN¥52.02 The company is down 29% from its price of CN¥73.20 on 03 July 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥4.17 per share. Announcement • Jul 08
Shanghai Sanyou Medical Co., Ltd. to Report First Half, 2020 Results on Aug 20, 2020 Shanghai Sanyou Medical Co., Ltd. announced that they will report first half, 2020 results on Aug 20, 2020 